Literature DB >> 21384289

Cerebral abnormalities in infants with myelomeningocele.

George A Alexiou1, Maria K Zarifi, George Georgoulis, Eleni Mpouza, Christiana Prodromou, Athina Moutafi, Marina Anagnostakou, George Sfakianos, Neofytos Prodromou.   

Abstract

BACKGROUND AND
PURPOSE: We evaluated brain abnormalities associated with myelomeningocele in infants.
MATERIAL AND METHODS: Between June 1995 and June 2008, 42 patients with myelomeningocele were treated in our hospital. Only 24 patients (13 males, 11 females, mean age 1.5 months, range 1 day - 11 months) were evaluated by both spinal and brain magnetic resonance imaging (MRI) and were enrolled in the study.
RESULTS: Brain MRI revealed: hydrocephalus in 21 (87.5%) patients, all of whom required immediate shunting. Total agenesis of the corpus callosum was observed in 2 (8.3%) patients, partial agenesis was seen in 4 (17%) patients and 8 (34%) patients had dysplasia of the corpus callosum. Absence of the septum pellucidum was observed in 2 (8%) patients. Widening of the interhemispheric fissure and colpocephaly were noted in 10 (41%) and in 3 (12%) patients, respectively. Abnormal white matter maturation was observed in 2 (8%) patients. Small posterior fossa was observed in 18 (74%) patients, Chiari malformation in 16 (67%) patients, cerebellar and brain stem hypoplasia in 3 (12%) and 7 (30%) patients, respectively.
CONCLUSIONS: MRI examination of the myelomeningocele site is not sufficient. Clinicians should consider obtaining imaging studies of the entire neuraxis in patients with myelomeningocele.

Entities:  

Mesh:

Year:  2011        PMID: 21384289     DOI: 10.1016/s0028-3843(14)60055-4

Source DB:  PubMed          Journal:  Neurol Neurochir Pol        ISSN: 0028-3843            Impact factor:   1.621


  1 in total

1.  Agenesis of the corpus callosum associated with spinal open neural tube defect.

Authors:  Essam A Elgamal; Sherif M Elwatidy; Amro F Alhabib; Zain B Jamjoom; Waleed R Murshid; Hamdy H Hassan; Mustafa A Salih
Journal:  Saudi Med J       Date:  2014-12       Impact factor: 1.484

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.